Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Maxim to close Ceplene treatment protocol and withdraw NDA

Nov. 4, 2004

Interleukin-12 produces responses in non-Hodgkin's lymphoma patients

Nov. 2, 2004

Provenge extends survival of advanced prostate cancer patients in phase III study

Nov. 2, 2004

Phase II study of IMOxine in renal cell carcinoma opens enrollment

Oct. 29, 2004

Phase I/II trial supports activity of epratuzumab in non-Hodgkin's lymphoma

Oct. 28, 2004

Peregrine discusses Tarvacin IND with FDA

Oct. 28, 2004

New NY-ESO-1-derived peptide and its use reported in a recent patent

Oct. 28, 2004

FDA approval for Campath single-dose vial

Oct. 20, 2004

AERES Biomedical completes humanization of Peregrine's 3G4 antibody

Oct. 20, 2004

Patients receive HGS-ETR1 in new cancer studies

Oct. 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...